Impact of CXCR4 inhibition on FLT3-ITD-positive human AML blasts

被引:30
|
作者
Jacobi, Angela [1 ]
Thieme, Sebastian [1 ,2 ]
Lehmann, Romy [1 ]
Ugarte, Fernando [1 ]
Malech, Harry L. [3 ]
Koch, Sina [4 ]
Thiede, Christian [2 ,4 ]
Mueller, Katrin [4 ]
Bornhaeuser, Martin [2 ,4 ]
Ryser, Martin [1 ]
Brenner, Sebastian [1 ,2 ]
机构
[1] Univ Clin Carl Gustav Carus Dresden, Dept Pediat, D-01307 Dresden, Germany
[2] Tech Univ Dresden, DFG Res Ctr & Cluster Excellence Regenerat Therap, Dresden, Germany
[3] NIAID, Host Def Lab, NIH, Bethesda, MD 20892 USA
[4] Univ Clin Carl Gustav Carus Dresden, Med Clin 1, D-01307 Dresden, Germany
关键词
ACUTE MYELOGENOUS LEUKEMIA; PERIPHERAL-BLOOD; FLT3; MUTATIONS; FLT3-ACTIVATING MUTATIONS; HEMATOPOIETIC-CELLS; PROGENITOR CELLS; STEM-CELLS; SURVIVAL; ENGRAFTMENT; CHEMOTAXIS;
D O I
10.1016/j.exphem.2009.12.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. Internal tandem duplication (ITD) mutations of the FLT3 receptor are associated with a high incidence of relapse in acute myeloid leukemia (AML). Expression of the CXCR4 receptor in FLT3-ITD-positive AML is correlated with poor outcome, and inhibition of CXCR4 was shown to sensitize AMI, blasts toward chemotherapy. The aim of this study was to evaluate the impact of FLT3-ITD on cell proliferation and CXCR4-dependent migration in human hematopoietic progenitor cells and to investigate their response to CXCR4 inhibition. Materials and Methods. We use primary blasts from patients with FLT3-ITD or FLT3 wild-type AML. In addition, human CD34(+) hematopoietic progenitor cells were transduced to >70% with retroviral vectors containing human FLT3-ITD. Results. We found that FLT3-ITD transgene overexpressing human hematopoietic progenitor cells show strongly reduced migration toward stromal-derived factor-1 in vitro and display significantly reduced bone marrow homing in nonobese diabetic severe combined immunodeficient mice. Cocultivation of FLT3-ITD-positive AML blasts or hematopoietic progenitor cells oil bone marrow stromal cells resulted in a strong proliferation advantage and increased early cobblestone area-forming cells compared to FLT3-wild-type AML blasts. Addition of the CXCR4 inhibitor AMD3100 to the coculture significantly reduced both cobblestone area-forming cells and proliferation of FLT3-ITD-positive cells, but did not affect FLT3-wild-type cells-highlighting the critical interaction between CXCR4 and FLT3-ITD. Conclusion. CXCR4 inhibition to decrease cell proliferation and to control the leukemic burden play provide a novel therapeutic strategy in patients with advanced FLT3-ITD-positive AML. (C) 2010 ISEH - Society for Hematology and Stern Cells. Published by Elsevier Inc.
引用
收藏
页码:180 / 190
页数:11
相关论文
共 50 条
  • [41] Discontinuation of sorafenib can lead to the emergence of FLT3-ITD-positive acute myeloid leukemia
    Kakiuchi, Seiji
    Yakushijin, Kimikazu
    Sakai, Rina
    Kawaguchi, Koji
    Higashime, Ako
    Kurata, Keiji
    Ichikawa, Hiroya
    Nagao, Shigeki
    Rikitake, Junpei
    Kiyota, Naomi
    Matsuoka, Hiroshi
    Minami, Hironobu
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (08) : 2010 - 2015
  • [42] FLT3 inhibitors upregulate CXCR4 and E-selectin ligands via ERK suppression in AML cells and CXCR4/E-selectin inhibition enhances anti-leukemia efficacy of FLT3-targeted therapy in AML
    Jia, Yannan
    Zhang, Weiguo
    Basyal, Mahesh
    Chang, Kyung Hee
    Ostermann, Lauren
    Burks, Jared K. K.
    Ly, Charlie
    Mu-Mosley, Hong
    Zhang, Qi
    Han, Xin
    Fogler, William E. E.
    Magnani, John L. L.
    Lesegretain, Arnaud
    Zal, Anna A. A.
    Zal, Tomasz
    Andreeff, Michael
    LEUKEMIA, 2023, 37 (06) : 1379 - 1383
  • [43] FLT3 inhibitors upregulate CXCR4 and E-selectin ligands via ERK suppression in AML cells and CXCR4/E-selectin inhibition enhances anti-leukemia efficacy of FLT3-targeted therapy in AML
    Yannan Jia
    Weiguo Zhang
    Mahesh Basyal
    Kyung Hee Chang
    Lauren Ostermann
    Jared K. Burks
    Charlie Ly
    Hong Mu-Mosley
    Qi Zhang
    Xin Han
    William E. Fogler
    John L. Magnani
    Arnaud Lesegretain
    Anna A. Zal
    Tomasz Zal
    Michael Andreeff
    Leukemia, 2023, 37 : 1379 - 1383
  • [44] SRC is a signaling mediator in FLT3-ITD-but not in FLT3-TKD-positive AML
    Leischner, Hannes
    Albers, Corinna
    Grundler, Rebekka
    Razumovskaya, Elena
    Spiekermann, Karsten
    Bohlander, Stefan
    Ronnstrand, Lars
    Goetze, Katharina
    Peschel, Christian
    Duyster, Justus
    BLOOD, 2012, 119 (17) : 4026 - 4033
  • [45] Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML
    Wu, H.
    Hu, C.
    Wang, A.
    Weisberg, E. L.
    Wang, W.
    Chen, C.
    Zhao, Z.
    Yu, K.
    Liu, J.
    Wu, J.
    Nonami, A.
    Wang, L.
    Wang, B.
    Stone, R. M.
    Liu, S.
    Griffin, J. D.
    Liu, J.
    Liu, Q.
    LEUKEMIA, 2016, 30 (03) : 754 - 757
  • [46] Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML
    H Wu
    C Hu
    A Wang
    E L Weisberg
    W Wang
    C Chen
    Z Zhao
    K Yu
    J Liu
    J Wu
    A Nonami
    L Wang
    B Wang
    R M Stone
    S Liu
    J D Griffin
    J Liu
    Q Liu
    Leukemia, 2016, 30 : 754 - 757
  • [47] The Role of Mcl-1 Expression and Phosphorlyation in Resistance to Chemotherapy and Kinase Inhibitors in FLT3-ITD-Positive Acute Myeloid Leukemia (AML)
    Heidel, Florian H.
    Schulze-Bergkamen, Henning
    Vick, Binje
    Lipka, Daniel B.
    Mirea, Fian K.
    Urbanik, Toni
    Opferman, Joseph T.
    Fischer, Thomas
    BLOOD, 2008, 112 (11) : 88 - 88
  • [48] Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia
    Oran, Betul
    Cortes, Jorge
    Beitinjaneh, Amer
    Chen, Hsiang-Chun
    de Lima, Marcos
    Patel, Keyur
    Ravandi, Farhad
    Wang, Xuemei
    Brandt, Mark
    Andersson, Borje S.
    Ciurea, Stefan
    Santos, Fabio R.
    Silva, Leandro de Padua
    Shpall, Elizabeth J.
    Champlin, Richard E.
    Kantarjian, Hagop
    Borthakur, Gautam
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (07) : 1218 - 1226
  • [49] Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapies
    Kasper, S.
    Breitenbuecher, F.
    Heidel, F.
    Hoffarth, S.
    Markova, B.
    Schuler, M.
    Fischer, T.
    BLOOD CANCER JOURNAL, 2012, 2 : e60 - e60
  • [50] Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapies
    S Kasper
    F Breitenbuecher
    F Heidel
    S Hoffarth
    B Markova
    M Schuler
    T Fischer
    Blood Cancer Journal, 2012, 2 : e60 - e60